Keen Eye, a French health tech company, announced the launch of its new AI (Artificial Intelligence) web-based platform dedicated to accelerating clinical trials, following GCLP (Good Clinical Laboratory Practices) principles.
The French company, building Deep Learning technology solutions for research and clinical studies, is strengthening its portfolio of products and services to reinforce its leadership in AI-based digital image analysis in Pathology. The company also keeps scalability in sight while building decision-support and GCLP-compliant solutions, striving to support the development of new therapies with better, faster, and more accurate analytics.
“It provides a quantum leap in performance while contributing to regulatory compliance, hence paving the way for better standards in clinical image analysis. We are proud to have developed the solution every pharma and CRO has been waiting for,” comments Sylvain Berlemont, CEO and founder of Keen Eye.
The company’s next-generation platform addresses the safety of clinical trial subjects along with the integrity of data. All action performed on the platform is captured by an audit trail, while several quality controls are implemented throughout workflows.
Dr. Jacques Bosq, former head of pathology at Institut Gustave Roussy, France, said “As pathologists, we always put patients’ interests first. Keen Eye’s expertise in digital tissue analysis has proven to be a really effective solution. With this innovative GCLP-compliant platform, pathologists will be able to perform biomarker detection and quantification in clinical study protocols in a reliable, standardized, and efficient manner.”
Keen Eye will showcase the platform capabilities during the “Biomarkers UK” event organized by Oxford Global, 08 – 09 November 2021.
